SENTARA COMMUNITY PLAN (MEDICAID)

MEDICAL PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

<u>Directions:</u> The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request. All other information may be filled in by office staff; <u>fax to 1-844-305-2331</u>. No additional phone calls will be necessary if all information (<u>including phone and fax #s</u>) on this form is correct. <u>If information provided is not complete</u>, correct, or legible, authorization can be delayed.

Drug Requested: Valstar® (valrubicin, intravesical) (J9357) (Medical)

MEMBER & PRESCRIBER INFO	DRMATION: Authorization may be delayed if incomplete.
Member Name:	
Member Sentara #:	
Prescriber Name:	
Prescriber Signature:	
Office Contact Name:	
Phone Number:	Fax Number:
DEA OR NPI #:	
DRUG INFORMATION: Authorizat	tion may be delayed if incomplete.
Drug Form/Strength:	
Dosing Schedule:	Length of Therapy:
Diagnosis:	ICD Code, if applicable:
Weight:	Date:
	the timeframe does not jeopardize the life or health of the member um function and would not subject the member to severe pain.
Quantity Limit (max daily dose) [NDC Unvials] via intravesical instillation once weekl	nit]: 800 mg (200 mg/5 mL in single-dose vials) [4 billable units = 4 y, retained for 2 hours
	ow all that apply. All criteria must be met for approval. To on, including lab results, diagnostics, and/or chart notes, must be
Length of authorization: One-time	authorization (6 weeks)
☐ Member is 18 years of age or older	
☐ Prescribed by or in consultation with	an oncology specialist

(Continued on next page)

PA Valstar (Medical)(Medicaid) (Continued from previous page)

	Member has a diagnosis of recurrent or persistent CIS of the urinary bladder
	Member has tried and failed intravesical Bacillus Calmette-Guérin (BCG) treatment, unless
	contraindicated or clinically significant adverse effects are experienced
	Cystectomy is <u>NOT</u> a therapeutic option as it would be associated with unacceptable morbidity or mortality
Me	dication being provided by (check applicable box(es) below):
	Location/site of drug administration:
-	NPI or DEA # of administering location:
	<u>OR</u>
	Specialty Pharmacy – Proprium Rx
reviev treatm	rgent reviews: Practitioner should call Sentara Pre-Authorization Department if they believe a standard w would subject the member to adverse health consequences. Sentara's definition of urgent is a lack of nent that could seriously jeopardize the life or health of the member or the member's ability to regain num function.
* 4	*Use of samples to initiate therapy does not meet step edit/ preauthorization criteria.**
* <u>Pre</u>	vious therapies will be verified through pharmacy paid claims or submitted chart notes.*